Page Title

This is a Paragraph. Click on "Edit Text" or double click on the text box to start editing the content and make sure to add any relevant details or information that you want to share with your visitors.

Publicatio

Publications

1. Heise CP, Saltzman DA, Hasz DE, Zebede M, Kelly SM, Curtiss III R, Leonard AS, and Anderson PM. Attenuated Salmonella typhimurium Containing Interleukin-2 Decreases Number of MC-38 Hepatic Metastases: A Novel Anti-tumor Agent. Cancer Biotherapy and Radiopharmaceuticals, 11(2)145-153, 1996.

2. Saltzman DA, Katsanis E, Hasz DE, Vigdorovich V, Curtiss III RE, Kelly SM, Anderson PM, and Leonard AS: Anti-tumor Mechanisms of Attenuated Salmonella typhimurium Containing the Gene for Human Interleukin-2. Journal of Pediatric Surgery, 32(2):301-306, 1997.

3. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Kelly SM, Curtiss R, Anderson PM, and Leonard AS: Hepatic and Splenic Colonization for the Attenuated Salmonella typhimurium Containing the Gene for Human Interleukin-2: A Novel Anti-Tumor Agent. Cancer Biotherapy and Radiopharmaceuticals, 12910:37-45, 1997.

4. Feltis BA, Sahr DA, Kim AS, Saltzman DA, Leonard AS, Sielaff TD: Cyclooxygenase 2 inhibition augments hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer. Diseases of the Colon and Rectum. 45(8):1023-8, 2002.

5. Soto LJ, Sorenson BS, Kim AS, Feltis BA, Leonard AS, and Saltzman DA: Attenuated Salmonella typhimurium prevents the Establishment of Hepatic Colorectal Metastases and Improves Survival in a Murine Model. Tumor Biology 23:S1:30, 2002.

6. Feltis BA, Miller JS, Sahar DA, Kim AS, Saltzman DA, Leonard AS, Wells, CL, and Sielaff TD: Liver and Circulating NK1.1(+)CD3(-) Cells are Increased in Infection with Attenuated Salmonella typhimurium and are Associated with Reduced Tumor in Murine Liver Cancer. Journal of Surgical Research 107(1):101-7, 2002.

7. Soto LJ, Sorenson BS, Kim AS, Feltis BA, Leonard AS, and Saltzman DA: Attenuated Salmonella typhimurium prevents the Establishment of Unresectable Hepatic Metastases and Improves Survival in a Murine Model. Journal of Pediatric Surgery 38(7) 1075-1079, 2003.

8. Nelson BW and Saltzman DA: Antioxidant oil augments cytotoxic immune response to attenuated Salmonella typhimurium. 17th Annual Life Sciences Undergraduate Research Symposium; College of Biological Sciences, University of Minnesota Press, Page 15, 2003.

9. Soto LJ, Sorenson BS, Nelson B, Solis S, Leonard AS, and Saltzman DA: Preferential Proliferation of Attenuated Salmonella typhimurium within Neuroblastoma. Journal of Pediatric Surgery 39(6), 937-940, 2004.

10. Soto LJ, Sorenson BS, Nelson BW, Leonard AS, Saltzman DA; Generation of Immunity to Hepatic Metastases by Attenuated Salmonella typhimurium, Ann Surg Onc, 11(2)suppl: S107, 2004.

11. Barnett SJ, Soto III LJ, Sorenson BS, Nelson BW, Leonard AS, Saltzman DA. Salmonella typhimurium Invades and Decreases Tumor Burden in Neuroblastoma.Journal of Pediatric Surgery 40(6): 993-998, 2005.

12. Saltzman DA. Cancer Immunotherapy Based on Killing of Salmonella typhimurium Infected Tumor Cells. Expert Opinion on Biological Therapy, 5(4)443-449, 2005.

13. Sean J. Barnett, Leland J. Soto, Brent S. Sorenson, Brent W. Nelson, Robert Bulander, Arnold S. Leonard, Daniel A. Saltzman. Attenuated Salmonella typhimurium in the treatment of neuroblastoma. Trends in Cancer Research, 3:47-52, 2007.

14. Brent S. Sorenson, BS, Kaysie L. Banton, MD, Natalie L Frykman, BS, Robert D. Acton MD, Arnold S. Leonard MD, PhD, Daniel A. Saltzman, MD, PhD. Attenuated Salmonella typhimurium with IL-2 gene Reduces Pulmonary Metastases in a Model of Osteosarcoma; Clinical Orthopaedics and Related Research. 466(6): 1285-91. 2008.

15. Brent S. Sorenson, BS, Kaysie L. Banton, MD, Natalie L Frykman, BS, Robert D. Acton MD, Arnold S. Leonard MD, PhD, Daniel A. Saltzman, MD, PhD. Attenuated Salmonella typhimurium with IL-2 gene Prevents the Establishment of Pulmonary Metastases in a Model of Osteosarcoma; J Ped Surg. 43(6): 1153-8. 2008.

16. Sorenson BS, Banton KL, Augustin LB, Barnett SJ, McCulloch KA, Dorn JM, Frykman NL, Leonard AS, Saltzman DA. Safety and Immunogenicity of Salmonella Typhimurium expressing C-terminal truncated Human IL-2 in a Murine Model. Biologics: Targets and Therapy. Biologics: Targets and Therapy. 2010 4:61-73.

17. Drees, JJ, Augustin LB, Mertensotto MJ , Schottel JL, Leonard AS, and Saltzman DA. Successful Production of Biologically Active Single-Chain Antibodies against Murine CTLA-4 and PD-L1 Protein Expression and Purification S1046-5928(13): 2013

18. Drees JJ, August LB, Mertensotto MJ, Schottel JL, Leonard AS, Saltzman DA: Soluble production of a biologically active single chain antibody against murine PDL-1 in E coli. PMID: 24215864 Protein Expr Purif 94:60-66, 2014.

19. Drees J, Mertensotto M, Liu G, Panyam, J, Leonard A, Augustin L, Schottel J, and Saltzman D: Attenuated Salmonella enterica Typhimurium Reduces Tumor Burden in an Autochthonous Breast Cancer Model. Anticancer Research, 35(2):843-849, 2015. PMID 25667465

20. Drees JJ, Mertensotto MJ, Augustin LB, Schottel JK. Saltzman DA: Attenuated Salmonella Vascular Disruption Enhances Bacterial Targeting of Autochthonous Tumors, 2015 Journal of Cancer, 6(9):843-848. PMID 26284135

21. Mertensotto MJ, Drees JJ, Augustin LB, Schottel JL, Leonard AS, and Saltzman DA: Expression of periplasmic chaperones in Salmonella Typhimurium reduces its viability in vivo. Curr Microbiol. 2015 Mar 70(3):433-5. PMID 25432864

23. Saltzman DA, Augustin LB, Leonard AS, Mertensotto M, and Schottel J: Low Dose Chemotherapy Combined with Attenuated Salmonella Significantly Reduces Tumor Burden and is Less Toxic than High Dose Chemotherapy in an Autochthonous Murine Model of Breast Cancer. Surgery, 163(3):509-514, 2018. PMID 29229318

24. Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G. White paper on microbial anti-cancer therapy and prevention. J Immunother Cancer. 2018;6(1):78. PMID: 30081947

25. Gniadek T, Augustin L, Schottel J, Leonard A, Saltzman D, Greeno E, Batist G. A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella Typhimurium Containing Human IL-2 in Patients with Metastatic Gastrointestinal Cancers. Journal of Immunotherapy. Volume 43(7): 217-221, September 2020 doi: 10.1097/CJI.0000000000000325.PMID: 32554977

26. Batist G, Park JY, Drees J, Kangas T, Saltzman D. Orally Administered Multiple Dose Saltikva (Salmonella-IL2) in Conjunction with Folfirinox in a Patient with Stage IV Pancreatic Cancer: A Case Report. Clinical Oncology: Case Reports. 2020;3(3).

27. Augustin L, Milbauer L, Hastings S, Leonard A, Saltzman D, and Schottel J: Salmonella enterica Typhimurium engineered for nontoxic systemic colonization of autochthonous tumors. Journal of Drug Targeting. DOI: 10.1080/1061186X.2020.1818759. September, 2020.

28. Augustin LB, Milbauer L, Hastings SE, Leonard AS, Saltzman DA, Schottel JL. Virulence-attenuated Salmonella engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer. J Drug Target. 2020 Dec 21:1-9. doi: 10.1080/1061186X.2020.1850739. PMID: 33183080.

29. Petr Kavan, Daniel A. Saltzman, Jule Muegge, Jordan Moradian, Gerald Batist. Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT035.

30. Saltzman D, Kavan P, Augustin L, Schottel J, Moradian J, Lee JT, Moradian E, and Batist G: Influence of salmonella-IL2 in combination with FOLFIRINOX on overall and progression-free survival in stage IV

Presentations

1. Heise CP, Saltzman DA, Kelly SM, Curtis III RE, and Anderson PM: Salmonella typhimurium – A Unique Vector for the Delivery of Interleukin-2 Increases NK Activity. Poster American Association of Cancer Researchers, San Francisco, CA, 1994.

2. Saltzman DA, Heise CP, Hasz DE, Eisenkraft TS, Kelly S, Curtiss III RE, Leonard AS, and Anderson PM; The Attenuated Salmonella Vector (ASV) for IL2: A New and Innovative Cancer Treatment Modality. Oral Presentation University of Minnesota Surgical Residents Association, Minneapolis, MN 1994.

3. Saltzman DA, Heise CP, Hasz DE, Eisenkraft TS, Kelly S, Curtiss III RE, Leonard AS, and Anderson PM: The Attenuated Salmonella Vector (ASV) for IL2: A New and Innovative Cancer Treatment Modality. Oral Presentation: Association for Academic Surgery, Albuquerque, NM, 1994.

4. Saltzman DA, Heise CP, Hasz DE, Eisenkraft TS, Kelly S, Curtiss III RE, Leonard AS, and Anderson PM: The Attenuated Salmonella Vector (ASV) for IL2: A New and Innovative Cancer Treatment Modality. Oral Presentation: Minnesota Surgical Society, Minneapolis, MN 1994.

5. Saltzman DA, Katsanis E, Heise CP, Hasz DE, Kelly SM, Curtiss R, Anderson PM and Leonard AS: Hepatic and Splenic Colonization for the Attenuated Salmonella typhimurium Containing the Gene for Human Interleukin-2: A Novel Anti-Tumor Agent. Surgical Infection Society, April, 1996, Milwaukee, WI.

6. Saltzman DA, Katsanis E, Hasz DE, Vigdorovich V, Curtiss III RE, Kelly SM, Anderson PM, and Leonard AS: Anti-tumor Mechanisms of Attenuated Salmonella typhimurium Containing the Gene for Human Interleukin-2. American Pediatric Surgical Association, May 1996. San Diego CA.

7. Saltzman DA, Katsanis E, Hasz DE, Vigdorovich V, Curtiss III RE, Kelly SM, Anderson PM, and Leonard AS: Anti-tumor Mechanisms of Attenuated Salmonella typhimurium Containing the Gene for Human Interleukin-2. Minnesota Surgical Residents Association Meeting, 1996.

8. Soto LJ, Sorenson BS, Kim AS, Feltis BA, Leonard AS, and Saltzman DA: Attenuated Salmonella typhimurium prevents the Establishment of Hepatic Colorectal Metastases and Improves Survival in a Murine Model. 30th Meeting of the International Society for Oncodevelopmental Biology and Medicine, Boston, MA, 2002.

9. Soto LJ, Sorenson BS, Kim AS, Feltis BA, Leonard AS, and Saltzman DA: Attenuated Salmonella typhimurium prevents the Establishment of Unresectable Hepatic Metastases and Improves Survival in a Murine Model. Annual Meeting, American Pediatric Surgical Association, 2002.

10. Saltzman DA: Attenuated Salmonella containing IL2: A novel antitumor agent. Annual Pediatric Conference, Istanbul, Turkey, May, 2009.

11. Saltzman DA: Making Friends with an Enemy: Salmonella for Cancer Therapy, TEDx Talk, Carleton College, September 2013.

12. Saltzman DA: Genetically Modified Salmonella for Cancer Therapy, Annual Meeting of Life Science Alley, 2015.

13. Saltzman DA: Project Stealth: Genetically Modified Salmonella for Cancer Therapy, Key Note Address of the Annual Meeting of Life Science Alley Association, 2016.

14. Saltzman DA: Genetically modified Salmonella for Cancer Therapy. Invited Speaker at NCI Consensus Conference on Bacterial Therapy for Cancer, July, 2017.

15. Saltzman DA: Daniel Saltzman MD PhD, Lance Augustin PhD, Arnold Leonard MD PhD, Michael Mertensotto BS and Janet Schottel PhD: Low Dose Chemotherapy Combined with Attenuated Salmonella Significantly Reduces Tumor Burden and is Less Toxic than High Dose Chemotherapy in an Autochthonous Murine Model of Breast Cancer, Central Surgical Society Annual Meeting, 2017.

16. Petr Kavan, Daniel A. Saltzman, Jule Muegge, Jordan Moradian, Gerald Batist. Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT035.

17. Saltzman D, Kavan P, Augustin L, Schottel J, Moradian J, Lee JT, Moradian E, and Batist G: Influence of salmonella-IL2 in combination with FOLFIRINOX on overall and progression-free survival in stage IV metastaticpancreaticcancerJCO 43, 25712571(2025).DOI:10.1200/JCO.2025.43.16_suppl.2571, 2025

Page Title

Section Title

List Title

List Title

List Title

List Title